Ascentage Pharma Secures China IND Clearance for BTK Degrader APG-3288
Summary
Ascentage Pharma announced that its novel BTK degrader, APG-3288, received IND clearance from China's CDE, enabling a Phase I clinical study for hematologic malignancies.
Key Events
-
China CDE IND Clearance for APG-3288
Ascentage Pharma's novel BTK degrader, APG-3288, received Investigational New Drug (IND) clearance from the China Center for Drug Evaluation (CDE).
-
Advances Global Clinical Development
This clearance, following a recent U.S. FDA IND clearance on January 7, 2026, enables a multicenter Phase I clinical study in China for patients with relapsed/refractory hematologic malignancies.
-
Strengthens Hematologic Malignancy Pipeline
The approval further strengthens Ascentage Pharma's pipeline in hematologic malignancies, building on its existing approved products in China.
Analysis
This IND clearance from the China CDE for APG-3288 is a significant positive development, expanding the drug's global clinical development program. Following the recent U.S. FDA IND clearance on January 7, 2026, it underscores the company's robust capabilities in targeted protein degradation and its commitment to addressing unmet medical needs in cancer across major markets. This milestone allows the company to initiate a Phase I study in China, further progressing its pipeline in hematologic malignancies.
At the time of this filing, AAPG was trading at $24.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $17.09 to $48.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.